Baichuan AI Adjustment Disbanded Its Financial Team, Focusing on AI Healthcare

Chinese AI unicore Baichuan AI has recently made significant adjustments to its business-to-business (B2B) operations. On March 3, 2025, the Business-end team, primarily responsible for the financial industry’s B2B business, was disbanded, with relevant employees signing termination agreements on the same day. Additionally, on February 19, 2025, the PE (Prompt Engineering) team, originally part of the B2B team, was transferred to the product and research group overseeing algorithm teams and consumer-end products.

In response, Baichuan AI stated that the company is optimizing and adjusting its financial business in accordance with its established plans to concentrate resources and focus on core businesses, thereby accelerating the development of AI-related medical technologies. Baichuan Intelligence revealed that its AI medical project has achieved significant milestones. Through a deep collaboration with Beijing Children’s Hospital, the jointly developed AI pediatrician has officially been deployed for expert consultations on complex cases, becoming the world’s first AI doctor formally applied in the medical field and receiving high recognition from expert panels.

Baichuan Intelligence plans to further integrate resources, enhance team operational efficiency, and promote the deep application of AI in the medical field to facilitate the popularization and accessibility of high-quality medical resources. This adjustment also indicates that Baichuan Intelligence is transitioning from a multi-business parallel model to a more focused strategy on AI in healthcare.

SEE ALSO: Tesla’s FSD Meets Challenges in Adapting to the Chinese Market

Report